Trials / Terminated
TerminatedNCT04483544
Pembrolizumab and Olaparib in Cervical Cancer Patients
Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Baptist Health South Florida · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pembrolizumab | PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks |
| DRUG | olaparib | PARP inhibitor olaparib 300 mg orally, twice daily (BID) |
Timeline
- Start date
- 2020-12-03
- Primary completion
- 2024-12-12
- Completion
- 2024-12-12
- First posted
- 2020-07-23
- Last updated
- 2025-04-29
- Results posted
- 2025-04-29
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04483544. Inclusion in this directory is not an endorsement.